ClinicalTrials.gg
RecruitingNCT05893693Updated Jun 8, 2023

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

An interventional study of Biological in Relapsed and/or Refractory Multiple Myeloma and Plasma Cell Leukemia in Relapse, sponsored by Aibin Liang,MD,Ph.D.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-08.

Sponsored by Aibin Liang,MD,Ph.D. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Plasma Cell with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Leukemia, Plasma Cell · China.

Planned enrollment
17th of 19
12 · median 24
Started
2023
with 5 others
No phase
3 of 20
2 open now
Primary completion
2026-01
later than 4 of 17 live
Registered
7th of 20
by date
Lead sponsor
1 of 20
Aibin Liang,MD,Ph.D.

Among the 20 studies in Leukemia, Plasma Cell with a site in China, this one is the 17th largest by planned enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 with no phase, reaches primary completion later than 4 of the 17 other live ones, and was the 7th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

17 of the 20 studies in Leukemia, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

Read the detailed description

This is an open-label, single arm, dose-escalation clinical study, to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

03

Conditions studied

  • Relapsed and/or Refractory Multiple Myeloma
  • Plasma Cell Leukemia in Relapse
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients and legally acceptable representative must have voluntarily signed ICF and willing to complete the study procedure, after fully understanding of the study.
  2. Age ≥ 18 years and ≤ 75 years, male or female.
  3. The patients, with MM or Plasma Cell Leukemia, who have received regimens and have medical records in the past.
  4. According to the IMWG consensus for multiple myeloma or Plasma Cell Leukemia, the disease is in a progressive state
  5. Subjects should have .

    5.1 Serum M protein ≥ 5 g / L;

    5.2 24-hour urinary M-protein ≥ 200 mg;

    5.3 The serum free light chain (sFLC) ratio was abnormal and the involved FLC ≥ 100mg/L in patients with light chain multiple myeloma whose serum or urinary M protein levels did not meet the assessable criteria.

    5.4 Circulating plasma cells ≥2%

  6. Expected survival > 12 weeks.
  7. (ECOG) scores 0-1.
  8. Subjects should have adequate function in hemostatic and liver and kidney.
  9. Women of childbearing age must undergo a serum pregnancy test with negative results at screening and before lymphodepletion and be willing to use an effective and reliable method of for at least 1 year after study treatment. All female subjects are prohibited from egg donation within 1 year after study treatment.
  10. Men must be willing to use an effective and reliable method of contraception for at least 1 year after study treatment if they have sexual activity with women of . All male subjects are prohibited from sperm donation within 1 year after study treatment .

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Subjects positive for any following tests: (HIV) antibody, Treponema pallidum (syphilis) antibody, CMV(IgM),EBV;
  3. Active and/or active (HCV RNA positive); Those who are positive for hepatitis B surface antigen and/or core antibodies but whose HBV-DNA test is within normal limits may be enrolled.
  4. Subjects with any uncontrolled active infection (Except for prophylactic treatment).
  5. Subjects with AEs from previous treatment that have not recovered to (CTCAE) ≤ 1, excluding hair loss and other events that the treating physician considers as tolerable.
  6. Subjects who have received autologous BCMA CAR-T therapy
  7. Subjects who have received stem cell transplantation for MM.
  8. Subjects who have received autologous stem cell transplantation less than 12 weeks before ICF.
  9. Subjects who have received any anti-MM treatment 14 days before ICF; the subjects are eligible to participate in the study regardless of the radiotherapy end date if the radiation area less than 5% of whole body.
  10. Subjects who have received systemic within 7 days before infusion, except inhaled steroids.
  11. Subjects who have been received within 8 weeks or inactivated vaccine within 4 weeks before lymphodepletion.
  12. Subjects have severe allergy history.
  13. Subjects who have any uncontrolled disease conditions within 6 months prior to the screening.
  14. \< 50%
  15. Blood oxygen saturation that can only be maintained at > 95% by oxygen inhalation.
  16. Subjects known to have active diseases including but not limited to psoriasis, rheumatoid arthritis and other conditions that require long-term therapy.
  17. Subjects with malignant tumors that have not been cured in the past 5 years or at the same time, except for very low malignant tumors.
  18. Subjects who have central nervous system (CNS) or symptomatic CNS involvement.
  19. Subjects who are unable or unwilling to comply with the requirements of clinical trial or other reasons that are not suitable for participating in the clinical trial.
  20. Subjects who have received major surgery 2 weeks prior to the screening or plan to receive major surgery within 4 weeks after study treatment (excluding cataract and other local anesthesia).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CT0594CP CAR-T Cells [BCMA-UCAR-T (CT0594)andCD94-UCAR-T(CT7590) ]

    CT0594CP

    Other: Biological

Interventions

  • OtherBiological

    CT0594CP

06

What researchers measure

Primary outcomes

  1. Safety and tolerability dose limiting toxicity

    Safety and tolerability: dose limiting toxicity \[Time Frame: 21-28 days post administration of CT0594CP \]

    Time frame: 21-28 days

Secondary outcomes

  1. Pharmacokinetics of CT0594CP CAR-T Cells (Tmax)

    peak plasma Concentration time(Tmax), of after infusion CT0594CP CAR T Cells

    Time frame: From first dose of study drug adminisration to end of treatment (up to 12 months)

  2. Pharmacokinetics of CT0594CP CAR-T Cells (Cmax)

    peak plasma Concentration(Cmax), of after infusion CT0594CP CAR T Cells

    Time frame: From first dose of study drug adminisration to end of treatment (up to 12 months)

  3. Pharmacokinetics of CT0594CP CAR-T Cells (AUC)

    area under the Plasma concentration versus time curve (AUC), of after infusion CT0594CP CAR T Cells

    Time frame: From first dose of study drug adminisration to end of treatment (up to 12 months)

  4. To evaluate the overall safety and tolerability of CT0594CP

    Post-treatment Adverse events (TEAE) and incidence, Special Concern Adverse Events (AESI) and incidence, treatment-related adverse events

    Time frame: From first dose of study drug administration to end of treatment (up to 12 months)

  5. To evaluate the initial efficacy of CT0594CP infusion in target subjects

    Overall response rate (ORR)、 Complete response/strict complete response (CR/sCR) rate、Response rates of VGPR and above were achieved 、Duration of response (DOR)、Progression-free survival (PFS)、Overall survival (overall survival (OS)、Minimal residual disease (MRD) negative rate as measured by International Myeloma Working Group (IMWG) criteria after CT0594CP infusion

    Time frame: From first dose of study drug administration to end of treatment (up to 12 months)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Jan 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Jun 8, 2023
StartActual
Apr 12, 2023
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2026
Last update
Jun 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05893693
Lead sponsor
Aibin Liang,MD,Ph.D.
Collaborators
CARsgen Therapeutics Co., Ltd.
Responsible party
Aibin Liang,MD,Ph.D. (Director of hospital, Shanghai Tongji Hospital, Tongji University School of Medicine) — Sponsor-investigator
First posted
Jun 8, 2023
Start date
Apr 12, 2023
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Jun 8, 2023

Study contacts

Aibin Liang
Contact
lab7182@tongji.edu.cn
+8618601670600
Ping Li
Contact
lilyforever76@126.com
+86 13564181131
Aibin Liang
principal investigator · +8618601670600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion